Search results for " CARDIOVASCULAR RISK"

showing 10 items of 115 documents

Echocardiographic Evaluation of the Cardiac Chambers in Asthmatic Patients: The BADA (Blood Pressure Levels, Clinical Features and Markers of Subclin…

2022

The “Blood pressure levels, clinical features and markers of subclinical cardiovascular Damage of Asthma patients” (BADA) study is aimed at defining the cardiovascular risk profile and the markers of subclinical and clinical vascular and cardiac damage in asthmatic patients. Very few studies have assessed asthmatic patients without concomitant heart disease through a transthoracic echocardiogram. The goal of the present study is to investigate the prevalence of morphology and/or function changes in the cardiac chambers of a sample of 86 patients with chronic asthma, referred to the dedicated outpatient unit of the Division of Respiratory Diseases of the AOUP “P. Giaccone&r…

asthma; cardiovascular risk; echocardiography; cardiac damage; essential hypertension; inhaled corticosteroid therapy; beta-adrenergic agonist agentscardiovascular riskbeta-adrenergic agonist agentessential hypertensioninhaled corticosteroid therapy.Medicine (miscellaneous)cardiac damageechocardiographyasthma
researchProduct

Blood pressure and cardiovascular risk profiles of africans who migrate to a Western country

2008

blood pressure cardiovascular risk hypertension
researchProduct

Myocardial infarction in Young adults: risk factors, clinical characteristics and prognosis according to our experience

2013

Objectives. Myocardial infarction is a relatively unusual phenomenon in young subjects. The aim if this work is to characterize the risk profile and factors influencing outcomes of these patients since it makes possible to manage prevention interventions. Patients and Methods. We examined cardiovascular risk factors, clinical presentation, angiographic picture and outcome of a group of young patients hospitalized for a myocardial infarction. We enrolled 121 young patients consecutively admitted to our hospital for a myocardial infarction and examined them not only at the initial stage, but also after 3 months and one year; finally a long-term telephonic follow up was performed, when possibl…

cardiovascular prevention cardiovascular risk factors coronary artery disease ischemic heart disease myocardial infarction young adults
researchProduct

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia.

2010

Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25% from baseline in monotherapy and on top of statins and fibrates. Yet, it seems that ezetimibe produces quantitative rather than qualitative changes in LDL, with small net effects on atherogenic dyslipidaemia. This is supported by findings from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression, where the addition of ezetimibe to simvastatin in patients with heterozygous familial hypercholesterolaemia did not affect the mean change in carotid int…

cardiovascular riskAortic valvemedicine.medical_specialtydyslipidaemiamedicine.drug_classezetimibe cardiovascular risk atherosclerosis dyslipidaemiachemistry.chemical_compoundEzetimibeInternal medicineClinical endpointMedicineCholesterol absorption inhibitorcardiovascular diseasesReview Paperbusiness.industryCholesterolnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseStenosismedicine.anatomical_structureEndocrinologychemistrySimvastatinCardiologylipids (amino acids peptides and proteins)atherosclerosisbusinessezetimibeLipoproteinmedicine.drug
researchProduct

Cardiovascular Health in Migrants. Current status and issues for prevention. A Collaborative Multidisciplinary Task Force Report

2014

OBJECTIVES: To review information on cardiovascular health and migration, to stress the attention of researchers that much needs to be done in the collection of sound data in Italy and to allow policy makers identifying this issue as an important public health concern. BACKGROUND: In Italy, the rate of immigrants in the total number of residents increased from 2.5% in 1990 to 7.4% in 2010, and currently exceeds 10% in regions such as Lombardia, Emilia Romagna and Toscana. METHODS: A consensus statement was developed by approaching relevant Italian national scientific societies involved in cardiovascular prevention. Task force members were identified by the president and/or the boards of eac…

cardiovascular riskMalemedicine.medical_specialtyEconomic growthcardiovascular risk; ethnic; ethnicity; global health; immigration; migrant; minorities; Cardiovascular Diseases; Diabetes Mellitus; Europe; Female; Health Status; Humans; Kidney Diseases; Male; Overweight; Transients and Migrants; Cardiology and Cardiovascular Medicine; Medicine (all)Kidney Diseasemedia_common.quotation_subjectHealth StatusImmigrationEthnic groupglobal healthHealth StatuminoritieCardiovascular DiseaseGlobal healthmedicineDiabetes Mellitusmedia_common.cataloged_instanceHumansEuropean unionethnicmedia_commonTransients and Migrantscardiovascular risk ethnic ethnicity global health immigration migrant minoritiesbusiness.industryPublic healthMedicine (all)Diabetes MellituGeneral MedicineOverweightminoritiesSettore MED/11 - Malattie Dell'Apparato CardiovascolareEuropemigrantCardiovascular Diseasesethnic; global health; immigration; migrant; minorities; cardiovascular risk; ethnicitySurvey data collectionethnicitySocial exclusionKidney DiseasesFemalebusinessCardiology and Cardiovascular MedicineDiversity (politics)immigrationHuman
researchProduct

Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance.

2015

Renal dysfunction is an independent predictor for cardiovascular morbidity and mortality. We investigated whether chronic hepatitis C virus (HCV) infection and the related insulin resistance/hyperinsulinemia influence renal function in comparison with a group of healthy subjects and with another group with metabolic syndrome. We enrolled 130 newly diagnosed HCV outpatients matched for age and gender with 130 patients with metabolic syndrome and 130 healthy subjects. Renal function was evaluated by calculation of glomerular filtration rate (e-GFR, mL/min/1.73 m2) using the CKD-EPI equation. The following laboratory parameters were measured: fasting plasma glucose and insulin, total, LDL- and…

cardiovascular riskMalemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentRenal function030204 cardiovascular system & hematologyurologic and male genital diseasesKidney Function Testschronic C hepatitis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInsulin resistanceChronic C hepatitis Renal function Insulin resistance Cardiovascular risk Metabolic syndromeInternal medicineInternal MedicinemedicineHyperinsulinemiaHumansMetabolic SyndromeCreatinineTriglyceridebusiness.industryInsulinrenal functionCase-control studyHepatitis C ChronicMiddle Agedmedicine.diseaseEndocrinologychemistryCase-Control Studieschronic C hepatitis; renal function; insulin resistance; cardiovascular risk; metabolic syndromeEmergency Medicine030211 gastroenterology & hepatologyFemaleMetabolic syndromeInsulin ResistancebusinessBiomarkersGlomerular Filtration RateInternal and emergency medicine
researchProduct

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid…

2022

Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond regulating LDL cholesterol (LDL-c) plasma levels, exerts several pleiotropic effects by modulating lipid metabolism in extrahepatic cells such as macrophages. Macrophage cholesterol homeostasis depends on serum lipoprotein functions, including the HDL capacity to promote cell cholesterol efflux (CEC) and the serum capacity to promote cell cholesterol loading (CLC). The aim of this observational study was to investigate the effect of PCSK9 inhibitors (PCSK9-i) treatment on HDL-CEC and serum CLC in patients with familial hypercholesterolemia (FH). 31 genetically confirmed FH patients were recruited. Blood was collected and serum is…

cardiovascular riskSettore MED/09 - Medicina Internafamilial hypercholesterolemiaPCSK9 inhibitors cardiovascular risk cholesterol efflux capacity cholesterol loading capacity familial hypercholesterolemiaPCSK9 inhibitorsSettore BIO/14 - Farmacologiacholesterol loading capacityBiochemistry Genetics and Molecular Biology (miscellaneous)Molecular BiologyBiochemistrycholesterol efflux capacityPCSK9 inhibitors; cardiovascular risk; cholesterol efflux capacity; cholesterol loading capacity; familial hypercholesterolemiaFrontiers in molecular biosciences
researchProduct

European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subcl…

2011

Item does not contain fulltext Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.

cardiovascular riskischemic-heart-diseaseHealth aging / healthy living [IGMD 5]coronary-artery-diseaseapolipoprotein-b metabolismcholesteryl ester transferAtherosclerosisstatementfamilial combined hyperlipidemialdlLipoproteins LDLvery-low-densitynuclear-magnetic-resonancec-reactive proteinRisk FactorsAnimalsHumansGenetic Predisposition to DiseaseLDL subclasses atherosclerosis cardiovascular risk statementsubclassesatherosclerosistype-2 diabetes-mellitusintima-media thickness
researchProduct

Aortic Stiffness in HIV Infection with and without Antiretroviral Therapy. A Meta-analysis of Observational Studies

2020

Background: The risk of Cardiovascular (CV) events is higher in HIV-infected patients (HIV+) compared to HIV-uninfected persons (HIV−). Large artery stiffness, a well-documented predictor of adverse CV prognosis, may mediate this enhanced risk. It is usually assessed by measuring aortic Pulse Wave Velocity (aPWV). Studies examining arterial stiffness in HIV+ yielded inconsistent results. We performed a meta-analysis with the aim to evaluate the association of HIV infection and its therapy [Antiretroviral Therapy (ART)] with aPWV. Design and Method: The Standardized Mean Difference (SMD) and corresponding 95% confidence intervals were calculated for aPWV in different comparison groups. Stati…

cardiovascular riskmedicine.medical_specialtySettore MED/09 - Medicina Internaaortic stiffnessSettore MED/17 - Malattie Infettivebusiness.industrypulse wave velocityHIV infection cardiovascular risk pulse wave velocity aortic stiffnessHuman immunodeficiency virus (HIV)virus diseasesSpecialties of internal medicineGeneral Medicinemedicine.disease_causeHIV infectionAntiretroviral therapyRC581-951Meta-analysisInternal medicineRC666-701MedicineDiseases of the circulatory (Cardiovascular) systemObservational studyAortic stiffnessbusinessPulse wave velocityArtery Research
researchProduct